Pharmacological activity of Salvinorin A, the major component of Salvia divinorum

Pharmacological Reports

Volumn 63, Issue 6, 2011, Pages 1305-1309

  Listos, Joanna ^a   Merska, Alicja ^a   Fidecka, Sylwia ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Salvia divinorum; Salvinorin A

Indexed keywords

CANNABINOID 1 RECEPTOR; DITERPENE; DIVINATORIN A; DIVINATORIN B; DIVINATORIN C; LYSERGIDE; NORBINALTORPHIMINE; PSYCHOTROPIC AGENT; RECREATIONAL DRUG; SALVINORIN A; SALVINORIN B; SALVINORIN C; SALVINORIN D; SALVINORIN E; SHORT ACTING DRUG; UNCLASSIFIED DRUG;

ADDICTION; ANIMAL BEHAVIOR; ANTIDEPRESSANT ACTIVITY; ANTINOCICEPTION; BEHAVIORAL SCIENCE; CHEMICAL COMPOSITION; CONCENTRATION RESPONSE; DIARRHEA; DRUG ANTAGONISM; DRUG INDICATION; DRUG MEGADOSE; DRUG STRUCTURE; HALLUCINATION; HUMAN; LAMIACEAE; LOCOMOTION; LOW DRUG DOSE; NONHUMAN; PLANT LEAF; REVIEW; SALVIA DIVINORUM; TRANQUILIZING ACTIVITY;

EID: 84857494905     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70694-6     Document Type: Review

References (23)

1. Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, Haliw LA, Walker SL: Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacology, 2009, 203, 203-211.
2. Braida D, Capurro V, Zani A, Rubino T, Viganò D, Parolaro D, Sala M: Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol, 2009, 157, 844-853.
3. Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, Zani A et al.: Involvement of κ-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry, 2008, 63, 286-292.
4. Butelman ER, Rus S, Prisinzano TE, Kreek MJ: The discriminative effects of the κ-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmacology, 2010, 210, 253-262.
5. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA et al.: Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther, 2004, 308, 1197-1203. (Pubitemid 38263998)
6. Ebner SR, Roitman MF, Potter DN, Rachlin AB, Chartoff EH: Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology, 2010, 210, 241-252.
7. Fichna J, Schicho R, Janecka A, Zjawiony JK, Storr M: Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Drug News Perspect, 2009, 22, 383-392.
8. Gehrke BJ, Chefer VI, Shippenberg TS: Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology, 2008, 197, 509-517.
9. González D, Riba J, Bouso JC, Gómez-Jarabo G, Barbanoj MJ: Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend, 2006, 85, 157-162. (Pubitemid 44468138)
10. Halpern JH: Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther, 2004, 102, 131-138.
11. Hanes KR: Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol, 2001, 21, 634-635.
12. http://www.sagewisdom.prg/legalstatus.html.
13. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, Nieto MJ: Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav, 2006, 83, 109-113.
14. Nemeth CL, Paine TA, Rittiner JE, Béguin C, Carroll FI, Roth BL, Cohen BM, Carlezon WA Jr: Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology, 2010, 210, 263-274.
15. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P et al.: Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Natl Acad Sci USA, 2002, 99, 11934-11939. (Pubitemid 34994502)
16. Roth BL, Lopez E, Beische, S, Evans JM: Screening the receptorome to discover molecular targets responsible for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther, 2004, 102, 99-110. (Pubitemid 38681010)
17. High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse, 2009, 63, 698-704.
18. Siebert DJ: Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol, 1994, 43, 53-56.
19. Valdés LJ: Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A: J Psychoactive Drugs, 1994, 26, 277-283.
20. Valdés LJ, Díaz JL, Paul AG: Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). J Ethnopharmacol, 1983, 7, 287-312. (Pubitemid 13078303)
21. Walentiny DM, Vann RE, Warner JA, King LS, Seltzman HH, Navarro HA, Twine CE Jr et al.: Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharmacology, 2010, 210, 275-284.
22. Willmore-Fordham CB, Krall DM, McCurdy CR, Kinder DH: The hallucinogen derived from Salvia divinorum, salvinorin A, has κ-opioid agonist discriminative stimulus effects in rats. Neuropharmacology, 2007, 53, 481-486. (Pubitemid 47284181)
23. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ: Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology, 2005, 179, 551-558. (Pubitemid 40674756)